Literature DB >> 7974292

Rise in total IgE as an indicator of allergic bronchopulmonary aspergillosis in cystic fibrosis.

J L Marchant1, J O Warner, A Bush.   

Abstract

BACKGROUND: Allergic bronchopulmonary aspergillosis is a serious complication of cystic fibrosis and may be difficult to diagnose. The aim of this study was to define the usefulness of measuring total IgE compared with other major criteria in the diagnosis of allergic bronchopulmonary aspergillosis in children with cystic fibrosis.
METHODS: A retrospective analysis was carried out of the case records of 160 children attending a tertiary referral paediatric cystic fibrosis clinic.
RESULTS: Sixteen children had a total IgE level above 500 IU/ml. Eleven children had six or more other major criteria and were considered to have allergic bronchopulmonary aspergillosis. These 11 children had a fourfold rise in IgE in association with clinical deterioration. A further child had a fourfold rise in IgE to 341 IU/l, and was also thought to have allergic bronchopulmonary aspergillosis. Eleven had a fall in IgE with successful treatment; one patient died with uncontrolled disease. Only one of these 12 children had negative precipitins to Aspergillus fumigatus. The five children with a raised IgE not thought to have bronchopulmonary aspergillosis had four or fewer major criteria and were not treated; none had positive precipitins.
CONCLUSIONS: A fourfold rise in total IgE, particularly to above 500 IU/ml, is strongly suggestive of the diagnosis of allergic bronchopulmonary aspergillosis in children with cystic fibrosis. The measurement of total IgE has the merit of being simple to perform and objective. Positive aspergillus precipitins provide useful confirmatory evidence. These two criteria, taken in conjunction with clinical deterioration and new radiological shadowing, allow simplification of the diagnosis of allergic bronchopulmonary aspergillosis in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7974292      PMCID: PMC475237          DOI: 10.1136/thx.49.10.1002

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  19 in total

1.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis.

Authors:  L E GIBSON; R E COOKE
Journal:  Pediatrics       Date:  1959-03       Impact factor: 7.124

2.  Five-year follow-up of allergic bronchopulmonary aspergillosis.

Authors:  B H Safirstein; M F D'Souza; G Simon; E H Tai; J Pepys
Journal:  Am Rev Respir Dis       Date:  1973-09

3.  Enteric-coated prednisolone in cystic fibrosis.

Authors:  J Gilbert; J M Littlewood
Journal:  Lancet       Date:  1986-11-15       Impact factor: 79.321

4.  Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis.

Authors:  M Rosenberg; R Patterson; R Mintzer; B J Cooper; M Roberts; K E Harris
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

5.  Atopy and bronchial reactivity in older patients with cystic fibrosis.

Authors:  M J Tobin; O Maguire; D Reen; E Tempany; M X Fitzgerald
Journal:  Thorax       Date:  1980-11       Impact factor: 9.139

6.  Allergic bronchopulmonary aspergillosis in three patients with normal chest x-ray films.

Authors:  M Rosenberg; R Mintzer; D W Aaronson; R Patterson
Journal:  Chest       Date:  1977-11       Impact factor: 9.410

7.  Analysis of bronchoalveolar lavage in allergic bronchopulmonary aspergillosis: divergent responses of antigen-specific antibodies and total IgE.

Authors:  P A Greenberger; L J Smith; C C Hsu; M Roberts; J L Liotta
Journal:  J Allergy Clin Immunol       Date:  1988-08       Impact factor: 10.793

8.  Unusual clustering of allergic bronchopulmonary aspergillosis in children with cystic fibrosis.

Authors:  S Maguire; P Moriarty; E Tempany; M FitzGerald
Journal:  Pediatrics       Date:  1988-12       Impact factor: 7.124

9.  Allergic bronchopulmonary aspergillosis: reactivity of IgE and IgG antibodies with antigenic components of Aspergillus fumigatus (IgE/IgG antigen complexes).

Authors:  J L Longbottom
Journal:  J Allergy Clin Immunol       Date:  1983-12       Impact factor: 10.793

10.  Allergic bronchopulmonary aspergillosis complicating cystic fibrosis in childhood.

Authors:  M J Brueton; L P Ormerod; K J Shah; C M Anderson
Journal:  Arch Dis Child       Date:  1980-05       Impact factor: 3.791

View more
  13 in total

Review 1.  Asthma in cystic fibrosis.

Authors:  Ian M Balfour-Lynn
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 2.  "CF asthma": what is it and what do we do about it?

Authors:  I M Balfour-Lynn; J S Elborn
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 4.  Treatment of severe small airways disease in children with cystic fibrosis: alternatives to corticosteroids.

Authors:  Adam Jaffe; Ian M Balfour-Lynn
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis.

Authors:  Nicole Ritz; Roland A Ammann; Carmen Casaulta Aebischer; Franziska Schoeni-Affolter; Martin H Schoeni
Journal:  Eur J Pediatr       Date:  2005-05-31       Impact factor: 3.183

6.  Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Authors:  Patrick Lebecque; A Leonard; M Argaz; Véronique Godding; Charles Pilette
Journal:  BMJ Case Rep       Date:  2009-03-05

Review 7.  Allergic bronchopulmonary aspergillosis.

Authors:  Richard B Moss
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

8.  Severe small airways disease resistant to medical treatment in a child with cystic fibrosis.

Authors:  J Davies; M Rosenthal; A Bush
Journal:  J R Soc Med       Date:  1996-03       Impact factor: 5.344

9.  Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children.

Authors:  I M Balfour-Lynn; U Mohan; A Bush; M Rosenthal
Journal:  Arch Dis Child       Date:  2004-04       Impact factor: 3.791

10.  Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab.

Authors:  Jennifer Collins; Gabriele Devos; Golda Hudes; David Rosenstreich
Journal:  J Asthma Allergy       Date:  2012-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.